Gossamer Bio, Inc. 8-K

What Happened
Gossamer Bio, Inc. (GOSS) filed an 8-K on June 17, 2026 furnishing a press release with final tender results for its previously announced exchange offer to exchange its 5.00% Convertible Senior Notes due 2027 for a pro rata mix of new securities. The exchange consideration may include up to $72.0 million aggregate principal of new 7.50% Convertible Senior Secured First Lien Notes due 2030, up to 317,647,058 shares of common stock (or prefunded warrants where shares would push certain holders above a 9.99% ownership cap), and warrants for certain eligible holders who tendered early. The filing also notes related stockholder proposals and a special meeting of stockholders scheduled for July 14, 2026 (definitive proxy was filed June 9, 2026).

Key Details

• Existing notes: 5.00% Convertible Senior Notes due 2027 are subject to the Exchange Offer.
• New debt offered: up to $72.0 million aggregate principal of 7.50% Convertible Senior Secured First Lien Notes due 2030.
• Equity/warrants: up to 317,647,058 shares of common stock may be issued; prefunded warrants used to avoid >9.99% ownership for certain Eligible Holders; additional warrants issued to Eligible Holders who tendered before the extended early tender date.
• Corporate actions: stockholder proposals tied to the Exchange Offer will be voted at a special meeting on July 14, 2026; proxy statement filed June 9, 2026.

Why It Matters
This transaction affects Gossamer’s capital structure—potentially replacing existing convertible debt with new secured first‑lien notes that carry a higher coupon (7.50%) and could result in significant equity issuance or warrants that dilute current shareholders. The special meeting and proxy materials are required for shareholder approval of related proposals, so investors should review the June 9, 2026 proxy and the June 17 press release for full terms, risks and timelines before voting or making investment decisions.